Nano-enabled lipid based drug delivery systems offer a platform to overcome challenges encountered with current failed leads in the treatment of parasitic and infectious diseases. When prepared with FDA or EMA approved excipients, they can be readily translated without the need for further toxicological studies, while they remain affordable and amenable to scale-up. Buparvaquone (BPQ), a hydroxynapthoquinone with in vitro activity in the nanomolar range, failed to clinically translate as a viable treatment for visceral leishmaniasis due to its poor oral bioavailability limited by its poor aqueous solubility (BCS Class II drug). Here we describe a self-nanoemulsifying system (SNEDDS) with high loading and thermal stability up to 6 months in tropical conditions able to enhance the solubilisation capacity of BPQ in gastrointestinal media as demonstrated by flow-through cell and dynamic in vitro lipolysis studies. BPQ SNEDDS demonstrated an enhanced oral bioavailbility compared to aqueous BPQ dispersions (probe -sonicated) resulting in an increased plasma AUC0-24 by 55% that is four fold higher than any previous reported values for BPQ formulations. BPQ SNEDDS can be adsorbed on low molecular glycol chitosan polymers forming solid dispersions that when compressed into tablets allow the complete dissolution of BPQ in gastrointestinal media. BPQ SNEDDS and BPQ solid SNEDDS demonstrated potent in vitro efficacy in the nanomolar range (<37 nM) and were able to near completely inhibit parasite replication in the spleen and 48 ± 48 and 56 ± 23% inhibition of the parasite replication in the liver respectively compared to oral miltefosine after daily administration over 10 days. The proposed platform technology can be used to elicit a range of cost-effective and orally bioavailable non-invasive formulations for a range of antiparasitic and infectious disease drugs that are needed for closing the global health innovation gap.
Graphical Abstract Introduction
Advances in biotechnology and drug delivery have transformed medicine in the industrialised world, but these innovations have yet to reach developing countries.
More than 10 million people in the developing countries die of infectious and parasitic diseases such as malaria, leishmaniasis, HIV/AIDS, tuberculosis, and diarrheal diseases annually, while morbidity related to these diseases devastates economic development 1 . More importantly, the burden of infectious and parasitic illness falls more heavily on children and pregnant women 2 .
Many of these diseases have earned the label of "neglected", because health-care markets in the affected countries are insufficient to attract pharmaceutical industry funding in research and development. These involve African Trypanosoniasis, Chagas diseases, dengue, leishmaniasis, leprosy, lymphatic filariasis, malaria, onchocerciasis, schistosomiasis and tuberculosis 3 . Over the past decade, publicprivate, not-for-profit, product development partnerships (PDPs) have arisen to tackle the development of new drugs, vaccines, diagnostics for developing-world diseases, while governments and foundations have increased their investment in neglected diseases research and development. The challenge remains to augment these public and private sector efforts by providing to those partnerships access to advanced technologies and expertise for discovering, delivering and developing new medicines 4 .
Leishmaniasis presents as cutaneous, mucosal and visceral forms caused by protozoa of the genus Leishmania that spread in humans through the bite of a phlebotomine sandfly 5 .
The cutaneous and mucosal forms cause severe disfigurement and disability resulting in gender inequality, stigmatisation and reduction of economic productivity 6 , while the visceral (VL) form is fatal if left untreated (with a 100% fatality rate within 2 years). An estimated 12 million people are infected with Leishmania with 50,000 deaths annually 7 , while 1.3 million new cases are reported every year putting in risk 310 million people 6 over a wider geographical distribution today due to urbanisation, migration and deforestation, making leishmaniasis a growing public health concern 8 . To complicate things further, up to twelve percent of all VL cases are associated with HIV/AIDS, while highest prevalence is reported in sub-Saharan countries (20-40% of cases) [9] [10] [11] .
First line treatment for VL relies on pentavalent antimonials [sodium stibogluconate (SSG) and N-methylglucamine antimoniate (meglumine antimoniate)] 12 . As resistance to antimonials is increasing limiting their use, emerging second-line treatments involve pentamidine and Amphotericin B (AmB) 13, 14 . AmB is highly effective in VL when administered intravenously. Available parenteral formulations involve an affordable micellar formulation (Fungizone ® ), which is highly nephrotoxic limiting the dose able to be administered, and a liposomal formulation (Ambisome ® ) with the latter used first line in the developed world. Other parenteral formulations involve lipidic complexes (Abelcet ® ), but these are less likely to be used due to their higher cost compared to Ambisome ® 13 . As AmB parenteral formulations are thermally unstable, cost of therapy is raised further to account for the need for cold transport and refrigeration. To overcome this issue, the clinical use of a heated Fungizone ® has been attempted in in India. This involved a 10-fold aqueous dilution of Fungizone ® and heating to 70 o C for 20 minutes 15 , which elicits larger AmB aggregates that are not renally cleared reducing observed nephrotoxicity 16 . Pentamidine, on the other hand, has been shown to cause insulin dependent diabetes which is irreversible and potentially fatal 17 .
Miltefosine, the only oral VL licensed treatment (licensed in 2003 in India), has a long elimination half-life (7 days) and a narrow therapeutic index. These pharmacokinetic characteristics limit the administered dose which can result in subtherapeutic levels over several weeks encouraging the emergence of resistance 18 . Indeed, resistance has been reported in India (a county that alone accounts for 50% of the VL worldwide burden) and France 13, 19 . Thus, available medicines for VL are outdated, impractical (non-oral, requiring hospitalisation and access to healthcare professionals over long treatment periods), insufficiently efficacious, or subject to resistance and unacceptable toxicities 4, [20] [21] [22] . Based on this, an ideal treatment for VL would possess greater than 95% efficacy, be orally administered, be stable in a tropical environment, be affordable and require less than 11 days treatment with an excellent side-effect profile 23 .
Buparvaquone (BPQ), a hydroxynapthoquinone licensed for theileriosis as an intramuscular injection, possesses promising activity in the nanomolar range against Leishmania spp. amastigotes (ED50: 0.005μM against L. donovani) 24 . Although in vitro experiments have provided promising results in the 90s, in vivo activity up to oral doses of 100 mg kg -1 has been low, due to its poor solubility in physiological fluids (<300 ng mL -1 , Log D: 7.02 at pH 3.0) and low oral bioavailability 24, 25 , which hindered its translation into a viable therapy. Attempts to improve BPQ's aqueous solubility and bioavailability have included the generation of water soluble BPQ phosphate prodrugs [26] [27] [28] , the use of nebulised nanosuspensions 29 BPQ nanosuspensions in mucoadhesive hydrogels 30 , oral suspensions and cyclodextrin complexes with limited success 31 . The most promising results towards an oral bioavailable BPQ formulations involved the use of self-emulsifying drug delivery system (SEDDS) 25 (Oleoylocapryoyl macragol-6 glycerides) were kindly provided by Gattefosse (Berkshire, UK) and soya phosphatidylcholine (Lipoid S100) by Lipoid GmbH (Rein, Germany). Pancreatin (porcine, P1625, ≥ 3 USP), bile extract (porcine) and all other chemicals, solvents, and acids, unless otherwise stated, were of ACS grade or above and were obtained from Sigma-Aldrich (Dorset, UK) and used without further purification. Cell culture media were bought from Sigma-Aldrich (Madrid, Spain).
Preparation of BPQ loaded SNEDDS (BPQ SNEDDS)
BPQ loaded SNEDDS (BPQ SNEDDS) were prepared by combining BPQ, Labrafil 1944CS (oleoyl macragol-6 glycerides), Capryol 90 (propylene glycol monocaprylate)
and Labrasol (caprylocaproyl macragol-8 glycerides) (0.01:3:1:5.99 w/w) under stirring at 600 rpm. This ratio was identified using pseudo-ternary phase diagram studies constructed with varying concentrations of oily solubilisers (Labrafil M 1944 CS) and oil soluble surfactants (Labrasol) and co-surfactants (Capryol 90) and double-distilled water using the water titration method at room temperature 25 ( Figure SI-1) . The samples were placed into a water bath at 37 ± 0.5°C for 24 hours under gentle shaking (Kotterman D1365, Hänigsen, Germany). Mixtures were then observed for turbidity when fresh and at 24 hours and particle size was measured when fresh and after 24 hours as described below. Turbidity is indicative of the formation of a coarse emulsion, whereas a clear isotropic solution would indicate a microemulsion (type II).
All formulations containing BPQ were protected from light. BPQ SNEDDS (10, 20 and 50 mg mL -1 ) were prepared in triplicate as described above to determine the maximum BPQ loading within the SNEDDS. After 24h, the samples were taken out from the waterbath and centrifuged at 10,000 rpm for 10 minutes (Jouan B4i centrifuge, Thermo Scientific, USA) and the supernatant was isolated and analysed using HPLC (after a 1 in 250 dilution with methanol) as described below.
Photon Correlation Spectroscopy (particle size & zeta potential measurements)
SNEDDS were diluted with water at 1 in 200 v/v and 1 in 100 v/v (pH 6.5) prior to particle size and zeta-potential measurements respectively (Malvern Zetasizer NanoZs, Malvern Instruments, Worcestershire, UK) at 25 o C and at a wavelength of 633 nm. The data were analysed using the Contin method of data analysis. Diluted suspensions were left for 15 minutes at room temperature (25°C) before particle size was measured. The accuracy of the instrument was assessed periodically using a drop of latex beads (polystyrene, mean size: 0.1 µm) in 50 mM sodium chloride (dispersed phase). All measurements (n=13) were performed in triplicate and the mean (±SD) was reported.
Zeta potential (Malvern Nano-Zs, Malvern Instruments, UK) was measured for the diluted formulations utilizing the Doppler electrophoresis technique. Analysis of the Doppler shift (Fourier transformed) was done by using a mixed-mode measurement phase analysis light scattering (M3-Pals). The viscosity of the sample was hypothesized to be the viscosity of water at 25 o C. All measurements (n=100) were performed in triplicate and the mean (±SD) was reported.
HPLC analysis
A modified reverse phase HPLC (RP-HPLC-UV) method based on the optimized and validated method published by Venkatesh et al 32 
Flow-through cell dissolution studies for BPQ SNEDDS
The dissolution of BPQ from BPQ-SNEDDs (10 mg mL -1 , 0.3mL) loaded capsules (NP CapsTM, pullulan, size 2, Capsugel) was studied in the flow through cell (USP, Apparatus IV) at various pH levels [USP 2013 simulated gastric fluid without enzyme (1.2), acetate buffer (4.5) and phosphate buffer (6.8), flow rate 6 ml min -1 ] as previously described 14 .
In vitro lipolysis
In vitro lipolysis experiments were performed as previously described 33 . The lipolysis medium contained bile salts (5 mM) and phosphatidylcholine (1 mM) which simulate fasted conditions in the gastrointestinal tract (GIT), while the digestion buffer (300 mL) was composed of sodium chloride (150 mM) and Trizma maleate (2 mM) at pH 6.5 ± 0.05 33 . A low buffer concentration was chosen to ensure that ionized fatty acids are able to change pH, while a buffer with low capacity was selected to allow the released fatty acids (FA) to reduce the pH and thus trigger the addition of sodium hydroxide 33 .
The lipase suspension was prepared by suspending pancreatin (16.6 g) in 110 mL of Millipore water at 37 o C and thoroughly mixing prior centrifugation (4,000 rpm, 7 minutes at 37 o C). The pH of the supernatant was adjusted to 6.5 using 1 M sodium hydroxide and 100 mL was used to initiate the lipolysis. To avoid denaturation, preparation of the pancreatin suspension never exceeded 15 minutes. For the in vitro digestion study, the lipolysis medium (300 mL) were pre-warmed at 37°C, prior to the addition of BPQ loaded SNEDDS (3g) and adjusting the pH to 6. 
Preparation of BPQ loaded solid SNEDDS (BPQ solid SNEDDS)
Low molecular weight glycol chitosan polymers were produced from 2 g of glycol chitosan that were added to freshly prepared 4M hydrochloric acid (152 mL), and stirred (500 rpm, IKA Werke RTC basic, IKA laboratories, Staufen, Germany) until homogenous (25 min) as previously described 34 Ltd, England) and stained with 1% aqueous Uranyl Acetate before TEM analysis as previously described (FEI CM120 BioTwin Transmission Electron Microscope) 35 .
Dry powders left to air dry was mounted on a glass slide that was mounted on a standard SEM sample holder and fixed on a brass/aluminium stub using double sided carbon impregnated adhesive discs. The sample was then sputtered coated with a conducting gold-palladium (10 nm, 60% gold-palladium) coating using a SEM coating 
Powder X-Ray Diffraction (PXRD)
PXRD analysis was performed with a Rigaku MiniflexII desktop X-ray diffractometer (Rigaku, Tokyo, Japan) attached to a Haskris cooling unit (Grove Village, IL, USA).
The PXRD patterns were recorded from 5° to 40° on the 2 theta at a step scan rate of 0.05° per second as previously described (n=3) 36 . X-ray powder patterns of single crystal structures were calculated using Mercury® (version 3.9., Cambridge
Crystallographic Data Centre, Cambridge, UK) and Miller's indices of various facets of the crystal were identified (SI-3) 37 . Mercury® was also used to predict the Bravais, Friedel, Donnay and Harker (BFDH) morphology to provide an insight into the molecular arrangement of different crystal facets of BPQ crystals (SI-3) 37 .
Thermal analysis
Differential Scanning Calorimetry (DSC) experiments were performed using a Mettler
Toledo DSC 821e (Greifensee, Switzerland) with a refrigerated cooling system (LabPlant RP-100, Filey, UK) as previously described 36 with nitrogen as the purge gas. Aluminum sample holders (40 μL) were sealed with a lid and pierced to provide three vent holes. Sample weight (3-6 mg) was sufficient to provide proper contact between the powder and the bottom of the pan. DSC measurements were carried out at a heating/cooling rate of 10°C min -1 . The unit was calibrated with indium standards.
The DSC system was controlled by Mettler Toledo STARe software (version 6.10)
working on a Windows NT operating system. Temperatures of melting and crystallisation events refer to onset temperatures. Details for thermogravimetric analysis (TGA) is provided in supplementary information (SI-4).
Fourier-Transformed Infra-red (FT-IR) spectroscopy
The infrared absorption spectra were obtained using a PerkinElmer Spectrum 1 FTIR Spectrometer (PerkinElmer, Massachusetts, USA) equipped with a Universal Attenuated Total Reflectance (UATR) accessory and a diamond/zinc selenide (4000 to 650 cm -1 ) crystal accessory 36 . Baseline correction and data normalization were performed using Spekwin32 version 1.71.6.1 (maximum resolution is 1 cm -1 ).
Hausner ratio and compressibility index of BPQ solid SNEDDS
BPQ solid SNEDDS (1 g) was placed in a 5 mL measuring cylinder and the volume was recorded. Tapped density was calculated by tapping cylinder into a hard surface 10, 20, 40, 60, 80, 100, 120, and 150 times, recording the volume after each set of taps. The Hausner ratio and compressibility index were determined as described by the equations below:
where Vo is the unsettled apparent volume and Vf is the final tapped volume.
Preparation and characterisation of BPQ solid SNEDDS tablets
Lyophilised BPQ solid SNEDDs (300 mg) or blank solid SNEDDS (300 mg) were compressed for 10 seconds under 1 bar of pressure using a flat-faced 12mm die (Specac manually operated hydraulic press, Analytical accessories Ltd, Kent, UK).
Disintegration was tested as specified in the British Pharmacopoeia 2018 38 . Tablets were placed in a basket rack assembly, and raised/lowered 30 times per minute at a distance of 55 ± 2 mm in 1L of water heated to 37.0 ± 0.5°C (Erweka disintegration tester ZT500 series, Erweka GmBH, Heusenstamm, Germany).
Friability studies were conducted using 10 BPQ solid SNEDDS tablets (300 mg)
according to British Pharmacopoeia 2018 method for uncoated tablets. Friability was expressed as the percentage of weight loss that was calculated by weighing the tablets after 100 rotations of the drum in 4 min. Tablets were dusted and accurately weighted.
Six BPQ solid SNEDDS tablets (300 mg) were crushed using a mortar and pestle and the powder was extracted with 50 mL of methanol, filtered using Whatman No 1 filter paper and the filtrate was made up to 100 mL with methanol in a volumetric flask. The concentration in the final solution was measured using HPLC as described above to identify the uniformity of content. The dissolution of six BPQ solid SNEDDS tablets
(300 mg) were tested using the basket method (Appendix I, BP 2018) using a GB Caleva Ltd Ascott model 657 dissolution apparatus, with a Tecam TE7 Tempette heating system. Tablets were immersed in 500 mL of pH 1.2 ± 0.1 for the first hour, after which 400 mL of pH 6.8 buffer were added and the final pH was adjusted to 6.8 using 5 M sodium hydroxide (between 4 -4.5 mL). The first media was prepared by mixing sodium chloride (2 M, 250 mL) and hydrochloric acid (2 M, 425 mL) and making them up to 1L with deionised water (pH 1.2). The second media contained 250 mL potassium dihydrogen phosphate (2 M, 250 mL) and sodium hydroxide (2 M, 112 mL) that were made up to 1L with deionised water (pH 6.8 and 100 U mL -1 of penicillin plus 100 μg mL -1 of streptomycin 39 .
Promastigote drug susceptibility was determined by using the sensitive fluorimetric resazurin model (Sigma-Aldrich®) as previously described by our group 40 . Briefly, 
Cytotoxicity studies on murine macrophages
J774 murine macrophages were grown in RPMI 1640 medium supplemented with 10%
heat-inactivated FBS (30 min at 56 °C), penicillin G (100 U mL -1 ) and streptomycin (100 μg mL -1 ) as previously described by our group 40, 53 . Cells in the pre-confluence phase were harvested with 0.03% EDTA-0.05% Trypsin in PBS for 20 minutes and maintained at 37 °C in a humidified environment with 5% CO2 (Hucoa-Erlöss, Forma
Scientific, Ohio, USA). Cytotoxicity studies were conducted using a resazurin assay The preparation of the parasites and the experimental infection were performed as previously described 14 . Each BALB/c mouse was infected with 10 7 promastigotes by intracardiac route using a syringe with 26 G needle.
Mice were randomly split into groups (n = 8). Treatment was started on day 21 postinfection. A negative control (distilled water) and positive control (miltefosine in distilled water 12mg kg -1 ) 43, 44 were dosed by oral gavage once daily for 10 consecutive days.
Oral BPQ SNEDDS and BPQ Solid SNEDDS (6 mg kg -1 ) groups were also dosed once daily for 10 consecutive days by oral gavage. Formulations were dosed as liquid suspensions of SNEDDS or solid SNEDDS (powders prior being compressed into tablets) via oral gavage. The final group received a BPQ in DMSO intramuscular dose (25 mg kg -1 , 50μL) in the hind leg at day 21 and 26. Animals were killed on day 35 post-infection. Spleen and liver from each animal were aseptically removed and weighted to quantify the parasite burdens. The parasite burden was quantified by the limit dilution assay as previously described 14 and the percentage suppression of parasite replication (PS) was calculated using the following equation where PC is the number of parasites in the control group per tissue weight (g) and PT
is the number of parasites after treatment per tissue weight (g) 45 .
Statistical Analysis
Microsoft Office Excel 2015 was used to analyse all data and graphs were plotted using Microcal Origin 6.0 or GraphPad Prism 7.0. Student t-test or one-way analysis of variance (ANOVA) with Tukey's post-hoc test were performed at a 5% level of significance using IBM SPSS Statistics 21.
Results
The optimal microemulsion region was achieved for SNEDDS prepared with BPQ: FT-IR analysis illustrated that BPQ exhibits two characteristics peaks, a sharp peak at 3300 cm -1 attributed to intramolecular hydrogen bonds between the hydroxyl group of BPQ and a peak at 1694cm -1 belonging to the quinine carbonyl group (aromatic group with 2 double bonded oxygens) ( Figure 4B ). Physical mixtures of BPQ and blank SNEDDS adsorbed on low molecular weight glycol chitosan shows a peak at 1639cm -1 indicative of crystalline BPQ. However, the absence of these peaks for BPQ solid SNEDDS points towards the formation of a solid dispersion ( Figure 4B ), due to hydrogen bonding between hydroxyl groups of glycol chitosan with the quinine carbonyl groups of BPQ and can further explain the enhanced oral bioavailability of BPQ 26, 27 . Adsorption of SNEDDs onto low molecular weight glycol chitosan (GC) polymers resulted in the formation of porous solids. (Figure 2E ). Glycol chitosan is a biocompatible carbohydrate polymer with good solubility in both acidic and neutral pH.
Apart from being known to act as a mucoadhesive and oral bioavailability enhancer 35, 49, 50 , chitosans can be used as a disintegrant through swelling and formation of a hydrogel with increasing water content and decreasing hydrogel content from the core to the surface 51 . Formation of a porous matrix aids disintegration and can speed up the dissolution process. Upon reconstitution of the pre-tabletting lyophilised BPQ SNEDDS adsorbed on glycol chitosan mix (BPQ solid SNEDDS), a nanosuspension was formed with a particle size similar to the original BPQ SNEDDS in terms of size, polydispersity and zeta potential (284 ± 4.6 nm, 0.372 ± 0.006, -28.5 ± 0.611 mV).
Thus, release of SNEDDS is possible after adsorption on solid carriers ( Figure 2C,   2D ).
BPQ SNEDDS adsorbed on low molecular weight glycol chitosan and croscarmellose sodium resulted in a pre-tabletting mix with passable flow characteristics (Hausner ratio and the compressibility index was calculated to be 1.34 ± 0.03 and 25.2 ± 1.52% respectively) 52 BPQ SNEDDS and BPQ solid SNEDDS showed potent in vitro efficacy in the nanomolar range against L Infantum amastigotes similar to BPQ in DMSO (IC50 for all <37 nM), while having negligible cytoxocity against murine macrophages ( Table 1 ).
The activity of the blank SNEDDS can be attributed to inclusion of Labrasol. We have recently reported that Labrasol (a mixed ester of capric and caprylic acid) possesses high antileishmanial activity in the micromolar range with acceptable cytotoxicity against murine macrophages 53 . Labrafil on the other hand did not illustrate activity against Leishmania parasites similarly to low molecular weight glycol chitosan polymers 53 . Both BPQ and BPQ SNEDDS illustrated a high selectivity index that are well above DNDi (Drug for Neglected Diseases initiative) accepted hit selection levels (<10 μM, SI>10) 54 . of BPQ remained solubilised avoiding precipitation in the GI tract available for absorption after 30 minutes and more than 10% was available for absorption even after 90 minutes which is double previous published reports for orally bioavailable SEDDS ( Figure 2B ) 47 . This is important to note, as our nanoemulsions were well below 300 nm and it is known that reducing the size of the emulsion increases the specific surface area of the lipids and thus the action of pancreatic lipases 67 . The presence of BPQ as an oil layer for 30 minutes can allow BPQ to be absorbed at a later stage enhancing the gastric residence time 68 .
The Target Product (treatment) Profile (TPP) for VL is based around the development of a safe, effective, oral, short-course (11 days maximum) VL drug formulations to replace current treatments. Ideally a solid dosage form with enhanced stability in tropical temperatures is likely to be more cost-effective. BPQ-SNEDDS illustrated stability up to 6 months in tropical conditions (40 o C, 75% relative humidity) in terms of drug content, particle size, colloidal stability and morphology ( Figure SI-2) . In an attempt to reduce the cost of a liquid filled capsule, we adsorbed BPQ SNEDDS on solid carriers to produce conventional solid dosage forms such as tablets. Aqueous dispersions of BPQ solid SNEDDS resulted in nanoemulsions of similar size and morphology ( Figure 2C, 2D) . Although the flow properties of BPQ solid SNEDDS could be improved by the addition of a glidant or use of micronized lactose, tablets were produced that passed pharmacopoeia disintegration and dissolution tests for immediate release tablets. Dissolution studies illustrated a pH mechanism of release with an initial burst release of BPQ from tablets in SGF that remained constant over 60 minutes that was followed by a complete release of the drug when the pH was raised to 6.8 ( Figure 6 ). Low molecular weight glycol chitosan polymers are biocompatible carbohydrate polymers with good solubility in both acidic and neutral pH 69, 70 . Chitosans are known to swell when exposed to aqueous media and the inclusion of a super-disintegrant enables the formation of pores to allow water penetration within the polymer gel structure. However, superdisintegrants are known to behave differently in acidic and neutral media 71 . Croscarmellose sodium (Ac-Di-Sol ©) has been shown to promote faster dissolution in neutral media than acidic 72 which can explain dissolution behaviour observed and favouring of BPQ release in simulated intestinal media.
Solid state characterisation of BPQ solid SNEDDS is critical to understand the interaction of BPQ with the solid carriers at the molecular level and assess whether the formation of a BPQ solid dispersion or BPQ amorphisation was possible.
Lyophilisation of BPQ in a method used for the production of solid SNEDDS did not result in amorphous BPQ (Figure 3b, 4b) . Similarly, attempts to amorphise BPQ by melt quenching which has been previously reported as a method to amorphise BCS Class II drugs were unsuccessful (Figure 3c ). This can be explained as PXRD analysis indicated a prominent Bragg peak at 6.55 2θ o which correlates with a hydrophobic surface formed by aromatic rings of BPQ (Plane 001) ( Figure SI-3) . Additionally, the intensity of the Bragg peak at 12.95 2θ o corresponding to plane 002 (location of carbonyl groups) was also high, which indicates that h-bonding is likely to occur between the drug and surrounding hydrogen group donors such as glycol chitosan. Table 1) . Both BPQ and BPQ SNEDDS showed excellent selectivity for parasite versus mammalian cells with a high selectivity index that are well above DNDi (Drug for Neglected Diseases initiative) accepted hit selection levels 54 and that of miltefosine. The high selectivity of BPQ is expected as there is a high degree of sequence divergence between the Leishmania and human cytochrome b proteins 57 .
In vivo pharmacokinetic studies demonstrated an earlier onset of action for BPQ SNEDDS compared to BPQ which supports the immediate release and enhanced solubilisation of BPQ in gastrointestinal media resulting in AUC0-24 that are four fold previous reported values for BPQ SNEDDS after a single oral administration 25 .
Although BPQ SNEDDS and BPQ solid SNEDDS were as efficacious as miltefosine in inhibiting parasite replication in the spleen, they were not able to control parasite replication in the liver. Interestingly, oral BPQ SNEDDS and BPQ solid SNEDDS (6 mg kg -1 , 10 oral doses over 10 days) were as efficacious as intramuscular doses of BPQ (25mg kg -1 , one dose at day 1 and one dose at day 5), indicating that the reasons resulting in limited inhibition of parasite growth in the liver was not related to the oral bioavaibility of BPQ and amount of BPQ reaching the liver, but possibly due to metabolism of BPQ in the liver. BPQ has been reported to be metabolised by mouse and rat liver microsomes into an inactive red-coloured metabolic product with a halflife of less than 10 minutes being a substrate for CYP2C9 (half-life 6 minutes) and CYPC19 half-life (4 minutes), while it was also metabolised by CYP3A4 (half-life 50 minutes) 28, 74, 75 . To overcome this issue and ensure orally bioavailable and efficacious BPQ formulations, further studies of combinations of BPQ with fluconazole, a potent CYP2C9, CYPC19 and CYP3A4 inhibitor shown to be efficacious in the treatment of visceral leishmaniasis 76, 77 can be prepared and formulated easily with described SNEDDS platform technology into patient compliant solid dosage forms (SNEDDS filled capsules or tablets). Additionally, preparing SNEDDS with a lower amount of long-chain triglycerides (i.e. Labrafil 1944CS ~30%w/w of final formulation) and a higher short and medium-chain triglycerides (e.g. Capryol 90 and Labrasol) can potentially decrease the accumulation of the formulation in the liver to reduce BPQ metabolism.
Conclusions
Nanotechnology-enabled drug delivery systems offer a tool for overcoming the challenges encountered with current drugs, failed leads such as BPQ and antigens by improving their efficacy (and thus duration of treatment), safety, bioavailability, halflife, while also by enabling controlled release over tailored period of times and specific site-targeted delivery of therapeutics. When made with FDA or EMA approved scalable excipients they can result in medicine that can be taken readily to phase III human studies providing therapeutic solutions to neglected tropical diseases. Our 
